hydroxychloroquine has been researched along with Cardiovascular Diseases in 67 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is often used as a first-line treatment of rheumatoid arthritis despite limited evidence on its cardiovascular risk." | 8.12 | Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. ( D'Andrea, E; Desai, RJ; Glynn, RJ; He, M; Kim, SC; Lee, H; Weinblatt, ME, 2022) |
| "To evaluate the association of hydroxychloroquine (HCQ) use with lipid profiles in a Veterans Affairs Rheumatoid Arthritis (VARA) cohort." | 7.80 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. ( Aujero, M; Cannon, G; Caplan, L; Davis, L; Kerr, G; Michaud, K; Mikuls, T; Richards, J; Sayles, H, 2014) |
| "Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases." | 6.58 | Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. ( Barnetche, T; Combe, B; Gaujoux-Viala, C; Hua, C; Lukas, C; Morel, J; Rempenault, C, 2018) |
| " Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus." | 5.41 | Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial. ( Boll, L; Cadaval Gonçalves, S; Cortes, A; Eibel, B; Irigoyen, MC; Martinez, D; Rossi, B; Tedesco Silva, LM; Waclawovsky, G, 2021) |
| "Hydroxychloroquine, when used to treat patients with rheumatoid arthritis or systemic lupus erythematosus, has been found to reduce cardiovascular disease (CVD)." | 5.22 | The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases. ( Porter, M; Weidman-Evans, E, 2022) |
| "Hydroxychloroquine is often used as a first-line treatment of rheumatoid arthritis despite limited evidence on its cardiovascular risk." | 4.12 | Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. ( D'Andrea, E; Desai, RJ; Glynn, RJ; He, M; Kim, SC; Lee, H; Weinblatt, ME, 2022) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "To evaluate the association of hydroxychloroquine (HCQ) use with lipid profiles in a Veterans Affairs Rheumatoid Arthritis (VARA) cohort." | 3.80 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. ( Aujero, M; Cannon, G; Caplan, L; Davis, L; Kerr, G; Michaud, K; Mikuls, T; Richards, J; Sayles, H, 2014) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| " Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization." | 2.94 | A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. ( Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020) |
| "The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020." | 2.66 | Cardiovascular manifestation and treatment in COVID-19. ( Chien, CS; Chou, SJ; Kuo, MJ; Leu, HB; Lin, TY; Su, YB; Yang, YP, 2020) |
| "Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine." | 2.66 | [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. ( Baranchuk, A; Barbosa, M; Márquez, MF; Mendoza, I; Nuñez, E; Sosa Liprandi, Á; Wyss Quintana, FS; Zaidel, EJ, 2020) |
| "Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system." | 2.66 | A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020) |
| "Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases." | 2.58 | Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. ( Barnetche, T; Combe, B; Gaujoux-Viala, C; Hua, C; Lukas, C; Morel, J; Rempenault, C, 2018) |
| "Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease." | 2.55 | Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. ( Afeltra, A; Fasano, S; Margiotta, DP; Navarini, L; Pantano, I; Pierro, L; Riccardi, A; Valentini, G, 2017) |
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| " Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports." | 1.62 | Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. ( Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T, 2021) |
| "We collected Systemic Lupus Erythematosus Disease Activity Index 2000 disease activity index during the cardiovascular event." | 1.62 | Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state. ( Abdel-Latif, A; Batool, A; Kazzaz, NM; McVeigh, ED; Stromberg, A, 2021) |
| "Primary aim was to assess prevalence and severity of potential and real drug-drug interactions (DDIs) among therapies for COVID-19 and concomitant medications in hospitalized patients with confirmed SARS-CoV-2 infection." | 1.62 | Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. ( Cantudo-Cuenca, MD; Contreras-Macías, E; Fernández-Fuertes, M; Gutiérrez-Pizarraya, A; Lao-Domínguez, FA; Macías, J; Morillo-Verdugo, R; Pineda, JA; Pinilla-Fernández, A; Rincón, P, 2021) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| "Patients with systemic lupus erythematosus (SLE) have increased rates of cardiovascular disease (CVD) that are one of the major causes of mortality." | 1.43 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. ( Alpay-Kanıtez, N; Aral, O; Artim-Esen, B; Demir, S; Erer, B; Gül, A; İnanç, M; Kamalı, S; Öcal, L; Omma, A; Pehlivan, Ö; Şahinkaya, Y, 2016) |
| "Patients with systemic lupus erythematosus (SLE) have a higher prevalence of subclinical atherosclerosis and higher risk of cardiovascular (CV) events compared to the general population." | 1.40 | Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. ( Ammirati, E; Banfi, M; Baragetti, A; Bottoni, G; Bozzolo, EP; Catapano, AL; Cianflone, D; Contri, R; Garlaschelli, K; Grigore, L; Manfredi, AA; Monaco, C; Norata, GD; Palini, AG; Pirillo, A; Sabbadini, MG; Scotti, I; Uboldi, P, 2014) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | 1.39 | Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.49) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.99) | 29.6817 |
| 2010's | 18 (26.87) | 24.3611 |
| 2020's | 46 (68.66) | 2.80 |
| Authors | Studies |
|---|---|
| Tedesco Silva, LM | 1 |
| Cortes, A | 1 |
| Rossi, B | 1 |
| Boll, L | 1 |
| Waclawovsky, G | 1 |
| Eibel, B | 1 |
| Cadaval Gonçalves, S | 1 |
| Irigoyen, MC | 1 |
| Martinez, D | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Singh, M | 1 |
| Smolenkova, I | 1 |
| Zheng, Y | 1 |
| Pushpakumar, S | 1 |
| Tyagi, SC | 1 |
| García, RD | 1 |
| Asensio, JA | 1 |
| Perdicaro, DJ | 1 |
| de Los Ángeles Peral, M | 1 |
| Weidman-Evans, E | 1 |
| Porter, M | 1 |
| Mikkelsen, RR | 1 |
| Hundahl, MP | 1 |
| Torp, CK | 1 |
| Rodríguez-Carrio, J | 1 |
| Kjolby, M | 1 |
| Bruun, JM | 1 |
| Kragstrup, TW | 1 |
| D'Andrea, E | 1 |
| Desai, RJ | 1 |
| He, M | 1 |
| Glynn, RJ | 1 |
| Lee, H | 1 |
| Weinblatt, ME | 1 |
| Kim, SC | 1 |
| Mo, DG | 3 |
| Du, MM | 3 |
| El Boussadani, B | 1 |
| Benajiba, C | 1 |
| Aajal, A | 1 |
| Ait Brik, A | 1 |
| Ammour, O | 1 |
| El Hangouch, J | 1 |
| Oussama, O | 1 |
| Oussama, B | 1 |
| Tahiri, N | 1 |
| Raissuni, Z | 1 |
| Khunti, S | 1 |
| Khunti, N | 1 |
| Seidu, S | 1 |
| Khunti, K | 1 |
| Funck-Brentano, C | 1 |
| Salem, JE | 1 |
| Nguyen, LS | 1 |
| Drici, MD | 1 |
| Roden, DM | 1 |
| Becker, RC | 1 |
| Yakoub-Agha, I | 1 |
| Kang, Y | 1 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Aggarwal, G | 1 |
| Henry, BM | 1 |
| Aggarwal, S | 1 |
| Bangalore, S | 1 |
| Su, YB | 1 |
| Kuo, MJ | 1 |
| Lin, TY | 1 |
| Chien, CS | 1 |
| Yang, YP | 1 |
| Chou, SJ | 1 |
| Leu, HB | 1 |
| Oren, O | 1 |
| Yang, EH | 1 |
| Gluckman, TJ | 2 |
| Michos, ED | 1 |
| Blumenthal, RS | 1 |
| Gersh, BJ | 1 |
| Zaidel, EJ | 1 |
| Wyss Quintana, FS | 1 |
| Sosa Liprandi, Á | 1 |
| Mendoza, I | 1 |
| Márquez, MF | 1 |
| Nuñez, E | 1 |
| Barbosa, M | 1 |
| Baranchuk, A | 1 |
| Lang, JP | 1 |
| Wang, X | 1 |
| Moura, FA | 1 |
| Siddiqi, HK | 1 |
| Morrow, DA | 1 |
| Bohula, EA | 1 |
| Wu, L | 1 |
| O'Kane, AM | 1 |
| Peng, H | 1 |
| Bi, Y | 1 |
| Motriuk-Smith, D | 1 |
| Ren, J | 1 |
| Colafrancesco, S | 1 |
| Scrivo, R | 1 |
| Barbati, C | 1 |
| Conti, F | 1 |
| Priori, R | 1 |
| Davoudi-Monfared, E | 1 |
| Rahmani, H | 1 |
| Khalili, H | 1 |
| Hajiabdolbaghi, M | 1 |
| Salehi, M | 1 |
| Abbasian, L | 1 |
| Kazemzadeh, H | 1 |
| Yekaninejad, MS | 1 |
| Simmering, JE | 1 |
| Polgreen, LA | 1 |
| Polgreen, PM | 1 |
| Teske, RE | 1 |
| Comellas, AP | 1 |
| Carter, BL | 1 |
| Tang, D | 1 |
| Li, J | 1 |
| Zhang, R | 1 |
| Kang, R | 1 |
| Klionsky, DJ | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Kara, E | 1 |
| Demirkan, K | 1 |
| Unal, S | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Tanriverdi, O | 1 |
| Ozcan, M | 1 |
| García-Saavedra, MB | 1 |
| Rosales-Gutiérrez, RR | 1 |
| Valverde, E | 1 |
| Chumbes-Aguirre, M | 1 |
| Alvarado, R | 1 |
| Polo, R | 1 |
| Azañero, R | 1 |
| Chávez, C | 1 |
| Goldman, A | 1 |
| Bomze, D | 1 |
| Dankner, R | 1 |
| Hod, H | 1 |
| Meirson, T | 1 |
| Boursi, B | 1 |
| Maor, E | 1 |
| Pers, YM | 1 |
| Padern, G | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Sosa-García, JO | 1 |
| Gutiérrez-Villaseñor, AO | 1 |
| García-Briones, A | 1 |
| Romero-González, JP | 1 |
| Juárez-Hernández, E | 1 |
| González-Chon, O | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Boari, GEM | 1 |
| Chiarini, G | 1 |
| Bonetti, S | 1 |
| Malerba, P | 1 |
| Bianco, G | 1 |
| Faustini, C | 1 |
| Braglia-Orlandini, F | 1 |
| Turini, D | 1 |
| Guarinoni, V | 1 |
| Saottini, M | 1 |
| Viola, S | 1 |
| Ferrari-Toninelli, G | 1 |
| Pasini, G | 1 |
| Mascadri, C | 1 |
| Bonzi, B | 1 |
| Desenzani, P | 1 |
| Tusi, C | 1 |
| Zanotti, E | 1 |
| Nardin, M | 1 |
| Rizzoni, D | 1 |
| Lee, Z | 1 |
| Rayner, CR | 1 |
| Forrest, JI | 1 |
| Nachega, JB | 1 |
| Senchaudhuri, E | 1 |
| Mills, EJ | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Isenberg, D | 1 |
| Ehrlich, H | 1 |
| Elkbuli, A | 1 |
| Shukla, AM | 1 |
| Segal, MS | 1 |
| Pepine, CJ | 1 |
| Cheung, AK | 1 |
| Shuster, J | 1 |
| Mohandas, R | 1 |
| Martinez, WM | 1 |
| Flint, JJ | 1 |
| Shah, SV | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Budhathoki, P | 1 |
| Shrestha, DB | 1 |
| Khadka, S | 1 |
| Rawal, E | 1 |
| McVeigh, ED | 1 |
| Batool, A | 1 |
| Stromberg, A | 1 |
| Abdel-Latif, A | 1 |
| Kazzaz, NM | 1 |
| Feldman, CH | 1 |
| Link, MS | 1 |
| Cantudo-Cuenca, MD | 1 |
| Gutiérrez-Pizarraya, A | 1 |
| Pinilla-Fernández, A | 1 |
| Contreras-Macías, E | 1 |
| Fernández-Fuertes, M | 1 |
| Lao-Domínguez, FA | 1 |
| Rincón, P | 1 |
| Pineda, JA | 1 |
| Macías, J | 1 |
| Morillo-Verdugo, R | 1 |
| Bradley, SM | 1 |
| Emmons-Bell, S | 1 |
| Mutharasan, RK | 1 |
| Rodriguez, F | 1 |
| Gupta, D | 1 |
| Roth, G | 1 |
| Shah, RU | 1 |
| Wang, TY | 1 |
| Khera, R | 1 |
| Peterson, PN | 1 |
| Das, S | 1 |
| Lee, TC | 1 |
| Senecal, J | 1 |
| Hsu, JM | 1 |
| McDonald, EG | 1 |
| Fasano, S | 3 |
| Pierro, L | 3 |
| Pantano, I | 2 |
| Iudici, M | 1 |
| Valentini, G | 3 |
| Soh, MC | 1 |
| Nelson-Piercy, C | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Margiotta, DP | 1 |
| Navarini, L | 2 |
| Riccardi, A | 2 |
| Afeltra, A | 2 |
| Rempenault, C | 1 |
| Combe, B | 1 |
| Barnetche, T | 1 |
| Gaujoux-Viala, C | 1 |
| Lukas, C | 1 |
| Morel, J | 1 |
| Hua, C | 1 |
| Keeling, SO | 1 |
| Bissonauth, A | 1 |
| Bernatsky, S | 1 |
| Vandermeer, B | 1 |
| Fortin, PR | 1 |
| Gladman, DD | 1 |
| Peschken, C | 1 |
| Urowitz, MB | 1 |
| Margiotta, DPE | 1 |
| Fangtham, M | 1 |
| Petri, M | 1 |
| Kerr, G | 1 |
| Aujero, M | 1 |
| Richards, J | 1 |
| Sayles, H | 1 |
| Davis, L | 1 |
| Cannon, G | 1 |
| Caplan, L | 1 |
| Michaud, K | 1 |
| Mikuls, T | 1 |
| Ammirati, E | 1 |
| Bozzolo, EP | 1 |
| Contri, R | 1 |
| Baragetti, A | 1 |
| Palini, AG | 1 |
| Cianflone, D | 1 |
| Banfi, M | 1 |
| Uboldi, P | 1 |
| Bottoni, G | 1 |
| Scotti, I | 1 |
| Pirillo, A | 1 |
| Grigore, L | 1 |
| Garlaschelli, K | 1 |
| Monaco, C | 1 |
| Catapano, AL | 1 |
| Sabbadini, MG | 1 |
| Manfredi, AA | 1 |
| Norata, GD | 1 |
| Chatterjee, S | 1 |
| Sarkate, P | 1 |
| Ghosh, S | 1 |
| Biswas, M | 1 |
| Ghosh, A | 1 |
| Achuthan, S | 1 |
| Ahluwalia, J | 1 |
| Shafiq, N | 1 |
| Bhalla, A | 1 |
| Pareek, A | 1 |
| Chandurkar, N | 1 |
| Malhotra, S | 1 |
| Demir, S | 1 |
| Artim-Esen, B | 1 |
| Şahinkaya, Y | 1 |
| Pehlivan, Ö | 1 |
| Alpay-Kanıtez, N | 1 |
| Omma, A | 1 |
| Erer, B | 1 |
| Kamalı, S | 1 |
| Gül, A | 1 |
| Aral, O | 1 |
| Öcal, L | 1 |
| İnanç, M | 1 |
| Sharma, TS | 1 |
| Wasko, MC | 1 |
| Tang, X | 1 |
| Vedamurthy, D | 1 |
| Yan, X | 1 |
| Cote, J | 1 |
| Bili, A | 1 |
| Apostolopoulos, D | 1 |
| Morand, EF | 1 |
| Katz, SJ | 1 |
| Russell, AS | 1 |
| Mirjafari, H | 1 |
| Al-Husain, A | 1 |
| Bruce, IN | 1 |
| Stein, JH | 1 |
| Hsue, PY | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Cleland, LG | 1 |
| Caughey, GE | 1 |
| James, MJ | 1 |
| Proudman, SM | 1 |
| van Halm, VP | 1 |
| Nurmohamed, MT | 1 |
| Twisk, JW | 1 |
| Dijkmans, BA | 1 |
| Voskuyl, AE | 1 |
| Turpie, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial[NCT04161339] | Phase 4 | 50 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | ||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications[NCT04727424] | Phase 3 | 6,246 participants (Anticipated) | Interventional | 2021-01-19 | Recruiting | ||
| Hydroxychloroquine for the Management of CVD in CKD[NCT03636152] | Phase 2 | 100 participants (Anticipated) | Interventional | 2018-12-14 | Recruiting | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa[NCT03275870] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2017-09-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Comparison of baseline and post-treatment Sartorius severity scoring Sartorius scoring: minimum 0, no maximum, higher scores mean a worse outcome (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline sartorius score | 6 month sartorius score | |
| Hydroxychloroquine Treatment | 23.3 | 17.7 |
Comparison of baseline and post-treatment self-reported quality of life Dermatology Life Quality Index score: minimum 0, maximum 30. higher scores mean worse outcome. (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline DLQI score | 6 month DLQI score | |
| Hydroxychloroquine Treatment | 14.7 | 6 |
25 reviews available for hydroxychloroquine and Cardiovascular Diseases
| Article | Year |
|---|---|
The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hydroxychloroqui | 2022 |
The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2022 |
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, | 2022 |
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascul | 2020 |
Cardiovascular manifestation and treatment in COVID-19.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; | 2020 |
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Topics: Antimalarials; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID- | 2020 |
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Cardiovascular Di | 2020 |
A current review of COVID-19 for the cardiovascular specialist.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card | 2020 |
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral | 2020 |
Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
Topics: Adaptive Immunity; Adult; Anticoagulants; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; C | 2020 |
[Cardiovascular implications of SARS-CoV-2 infection: A literature review].
Topics: Acute Coronary Syndrome; Algorithms; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme | 2020 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.
Topics: Azithromycin; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; | 2021 |
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Topics: Adult; Antibodies, Antiphospholipid; Aspirin; Cardiovascular Diseases; Female; Humans; Hydroxychloro | 2017 |
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, | 2018 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.
Topics: Annexin A5; Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Cardiovascular Diseases; | 2011 |
Cardiovascular risk factors in inflammatory arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Clinical | 2011 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
5 trials available for hydroxychloroquine and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Topics: Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbi | 2020 |
Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study.
Topics: Aspirin; Cardiovascular Diseases; Fibrinogen; Healthy Volunteers; Humans; Hydroxychloroquine; Platel | 2015 |
Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arachidonic Acid; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2006 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
38 other studies available for hydroxychloroquine and Cardiovascular Diseases
| Article | Year |
|---|---|
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.
Topics: Animals; Blood; Blood Physiological Phenomena; Cardiomegaly; Cardiovascular Diseases; Cardiovascular | 2021 |
Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Facto | 2022 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2023 |
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health C | 2020 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1 | 2020 |
Covid-19 treatment update: follow the scientific evidence.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials | 2020 |
Hydroxychloroquine in Covid-19: Does the end justify the means?
Topics: Antibody Formation; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiovascular Diseases; Corona | 2020 |
The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Azithromycin; Cardiotoxicity; Cardiovascula | 2020 |
Chloroquine in fighting COVID-19: good, bad, or both?
Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Drug A | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Questions asked through two examples of dilemmas of publication ethics in the process of COVID-19.
Topics: Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqui | 2020 |
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Topics: Adult; Aged; Antimalarials; Cardiovascular Diseases; Chloroquine; COVID-19; COVID-19 Drug Treatment; | 2021 |
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca | 2020 |
Experience in the management of severe COVID-19 patients in an intensive care unit.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Humanized; Antiviral Age | 2020 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COV | 2020 |
The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.
Topics: Antimalarials; Antiviral Agents; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design.
Topics: Cardiovascular Diseases; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; Renal In | 2021 |
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state.
Topics: Appalachian Region; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Kentucky; Lupus Ery | 2021 |
Few Adverse Cardiovascular Events Among Patients With Rheumatoid Arthritis Receiving Hydroxychloroquine: Are We Reassured?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine | 2021 |
Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Topics: Aged; Analgesics; Cardiovascular Diseases; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Diuret | 2021 |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry.
Topics: Aged; Antirheumatic Agents; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Cross-Sectio | 2021 |
Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19.
Topics: Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Publishing; | 2021 |
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Aspirin; Cardiovascular Diseases; Drug Synergism; Drug Therapy, Combina | 2017 |
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
Topics: Adult; Antimalarials; Antirheumatic Agents; Biological Products; Canada; Cardiovascular Diseases; Fe | 2018 |
Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular D | 2019 |
Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Studies; Cross-Se | 2014 |
Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.
Topics: Adult; ATP Binding Cassette Transporter 1; Biomarkers; Blood Pressure; Body Mass Index; Cardiovascul | 2014 |
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc | 2013 |
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular Diseases; Cross-Sectional | 2016 |
Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Comorbidity; Fema | 2016 |
Inflammation, immune activation, and CVD risk in individuals with HIV infection.
Topics: Anti-Inflammatory Agents; Aorta; Cardiovascular Diseases; Female; HIV Infections; Humans; Hydroxychl | 2012 |
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Case-Control Studies; Fe | 2006 |